Cadisegliatin_product_DataBase

Bioactivity	Cadisegliatin (TTP-399) is a potential, orally active liver-selective glucokinase (GK) activator. Cadisegliatin has antihyperglycaemic activity. Cadisegliatin can be used for the research of type 2 diabetes[1][2].
Invitro	Cadisegliatin (TTP-399) 增加大鼠肝细胞的葡萄糖代谢，15 nM 葡萄糖中乳酸和糖原的 EC50 值分别为 2.39 μM 和 2.64 μM [2].
In Vivo	TTP399（200 mg/kg，口服，口服）对禁食大鼠的血浆葡萄糖和胰岛素没有影响[2]。TTP399（75 或 150 mg/kg，每天，持续 4 周）改善 ob/ob 小鼠模型的葡萄糖稳态[2]。TTP399（50 mg/kg，每天，持续 13 周）在小型猪模型的口服葡萄糖耐量试验 (OGTT) 期间有效降低血浆葡萄糖[2] 。 Animal Model:
Name	Cadisegliatin
CAS	859525-02-3
Formula	C21H33N3O4S2
Molar Mass	455.63
Appearance	Solid
Transport	Room temperature in continental US; may vary elsewhere.
Storage	4°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Reference	[1]. International Nonproprietary Names for Pharmaceutical Substances (INN) [2]. Adrian Vella, et al. Targeting hepatic glucokinase to treat diabetes with TTP399, a hepatoselective glucokinase activator. Sci Transl Med. 2019 Jan 16;11(475):eaau3441.

PeptideDB